BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17762923)

  • 1. Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancer.
    Yoshioka Y; Inoue T
    Strahlenther Onkol; 2007 Sep; 183(9):490-6. PubMed ID: 17762923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy.
    Yoshida K; Yamazaki H; Nakamura S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshioka Y
    Anticancer Res; 2014 Jun; 34(6):3077-81. PubMed ID: 24922676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
    J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors of localised, locally advanced or metastatic prostate cancer].
    Joly F; Henry-Amar M
    Bull Cancer; 2007 Jul; 94(7 Suppl):F35-43. PubMed ID: 17845992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
    Nguyen PL; Chen MH; Hoffman KE; Katz MS; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):104-9. PubMed ID: 19286330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy.
    Abdollah F; Schmitges J; Sun M; Thuret R; Djahangirian O; Tian Z; Shariat SF; Briganti A; Perrotte P; Montorsi F; Karakiewicz PI
    Urology; 2011 Dec; 78(6):1363-7. PubMed ID: 22137704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Problems of the preoperative prediction of the pathological stage in prostate cancer].
    Konomoto T; Naito S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):21-5. PubMed ID: 12557700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
    Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
    BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How often do available preoperative risk factors accurately predict the risk assessed after surgery for localized prostate cancer?
    Laudano MA; Lambert SM; Masson P; McCann TR; Desai M; Benson MC; McKiernan JM
    BJU Int; 2009 Feb; 103(3):317-20. PubMed ID: 18778341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: time trends, outcome, and risk stratification.
    Yoshioka Y; Suzuki O; Kobayashi K; Teshima T; Yamada Y; Kotsuma T; Koizumi M; Kagawa K; Chatani M; Shimamoto S; Tanaka E; Yamazaki H; Inoue T
    Strahlenther Onkol; 2009 Jul; 185(7):446-52. PubMed ID: 19714306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
    Makarov DV; Trock BJ; Humphreys EB; Mangold LA; Walsh PC; Epstein JI; Partin AW
    Urology; 2007 Jun; 69(6):1095-101. PubMed ID: 17572194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
    Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
    Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of 2001 Partin tables in Turkey: a multicenter study.
    Eskicorapci SY; Karabulut E; Türkeri L; Baltaci S; Cal C; Toktas G; Akpinar H; Ozer G; Sozen S; Tokuc R; Lekili M; Soylu A; Albayrak S; Sahin H; Alpar R; Ozen H
    Eur Urol; 2005 Feb; 47(2):185-9. PubMed ID: 15661412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
    Roach M; Weinberg V; Nash M; Sandler HM; McLaughlin PW; Kattan MW
    J Urol; 2006 Dec; 176(6 Pt 2):S16-20. PubMed ID: 17084158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
    Zelefsky MJ; Kattan MW; Fearn P; Fearon BL; Stasi JP; Shippy AM; Scardino PT
    Urology; 2007 Aug; 70(2):283-7. PubMed ID: 17826490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.